Ain Shams Scholar Collection:

The Protective Role of Statins against 5-Fluorouracil- induced Oral Mucositis in Colorectal Cancer Patients-Narrative Review

2026-04-08T13:57:54Z

Title: The Protective Role of Statins against 5-Fluorouracil- induced Oral Mucositis in Colorectal Cancer Patients-Narrative Review Authors: Lotfy, Radwa S.; Aboelhassan, Rasha; El Wakeel, Lamiaa M.; Shawki, May

The Potential Therapeutic Benefit of Anti-Inflammatory and Antioxidant Supplements as Adjuvant Therapy in Juvenile Idiopathic Arthritis: A Comprehensive Review

2026-04-08T13:57:23Z

Title: The Potential Therapeutic Benefit of Anti-Inflammatory and Antioxidant Supplements as Adjuvant Therapy in Juvenile Idiopathic Arthritis: A Comprehensive Review Authors: Elsherif, Nourhan N; Shousha, Ghada A; Sabri, Nagwa; Shawki, May

Alpha Lipoic Acid as a Potential Radioprotective Agent against Radiation-Induced Oral Mucositis through its antioxidant and anti-inflammatory effects

2026-04-08T13:55:49Z

Title: Alpha Lipoic Acid as a Potential Radioprotective Agent against Radiation-Induced Oral Mucositis through its antioxidant and anti-inflammatory effects Authors: Rizkalla, Beshoy Anwar; Kelany, Mohamed Reda; Sabri, Nagwa Ali; Shawki, May Abstract: Abstract Purpose: The main aim of this review is to investigate the potential role of alpha-lipoic acid (ALA), which is a naturally occurring antioxidant in the prevention and management of radiation-induced oral mucositis (RIOM) in head and neck cancer patients undergoing radiotherapy sessions. It highlights the antioxidant, anti-inflammatory, and radioprotective effects of ALA found in preclinical and clinical studies. Methods: A comprehensive literature search was carried out using the Egyptian Knowledge Bank, PubMed, and Google Scholar databases by applying key terms such as “alpha-lipoic acid,” “oral mucositis,” “radiotherapy,” “antioxidants,” and “head and neck cancers“ to find important preclinical and clinical studies that were published in English. Findings: Numerous preclinical and clinical studies have demonstrated that the antioxidant and anti-inflammatory effects of ALA are beneficial in various diseases. Also, ALA showed protective effects against radiation-induced oral mucosal damage in three animal studies due to ALA’s ability to improve the activity of antioxidant enzymes, suppressing the pro-inflammatory signaling pathways, and reducing apoptosis in irradiated oral tissues. Implications: The potent anti-inflammatory and antioxidant properties demonstrated in clinical trials, as well as its radioprotective effects observed in animal studies, make alpha-lipoic acid (ALA) a promising supportive treatment for the management of RIOM in head and neck cancer patients. These effects also support its potential inclusion into clinical protocols in the future. However, this can only be applicable after performing further investigations and more extensive clinical trials in order to determine the ideal dose, effectiveness, and safety in RIOM patients.

Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density

2026-04-08T13:54:19Z

Title: Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density Authors: Sayed, Sherihan A; El Wakeel, Lamia M; Elseasi, Ahmad M; Shawki, May Abstract: Purpose To compare the effect of denosumab and alendronate on bone mineral density (BMD) in renal transplant recipients (RTRs) with low bone mass. Methods Patients were randomized to receive either denosumab subcutaneously (60 mg/6 months), oral alendronate (70 mg/week), or no treatment for 1 year. The three groups were prescribed daily calcium and vitamin D. Primary outcome was BMD assessed at lumbar spine, hip, and radius and measured by dual-energy X-ray absorptiometry (DEXA) at baseline and after 6 and 12 months. Adverse events and laboratory assessments (calcium, phosphate, vitamin D, renal functions, and intact parathyroid hormone) were monitored for all patients. Quality of life was assessed at baseline and after 6 and 12 months for all patients. Results Ninety RTRs were included in the study (30 in each group). Baseline clinical characteristics and BMD values were comparable in the three groups. After 12 months, lumbar spine T-score of patients treated with denosumab and alendronate showed a median increase of 0.5 [95% confidence interval (CI): 0.4–0.6] and 0.5 (95% CI: 0.4–0.8), respectively, and patients in the control group showed a decrease of −0.2 (95% CI: −0.3 to −0.1), p < 0.001. Denosumab and alendronate showed a significant comparable gain in T-scores at hip and radius versus a significant decrease in the control group. Adverse events and laboratory values were similar in the three groups. Both treatments resulted in comparable significant improvement in physical functioning, physical role limitations, vitality, and pain scores. Conclusion Denosumab and alendronate showed comparable efficacy in improving BMD at all measured skeletal sites and were safe and well-tolerated, with no serious adverse effects reported in RTRs with low bone mass. The study was registered on ClinicalTrials.gov, number NCT04169698.